CVRX · XBRL financial data

CVRx financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CVRX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	13,036	22,469	39,295	51,292	56,651
Cost of revenue	3,640	4,999	6,256	8,334	8,311
Gross profit	9,396	17,470	33,039	42,958	48,340
Research and development	7,501	9,952	11,633	11,131	11,132
Selling, general and administrative	27,863	50,045	64,509	91,317	88,473
Total operating expenses	35,364	59,997	76,142	102,448	99,605
Operating income (loss)	(25,968)	(42,527)	(43,103)	(59,490)	(51,265)
Interest expense	2,219	165	1,799	4,397	5,827
Other income (expense)	(14,800)	1,373	3,850	3,977	3,768
Income tax expense (benefit)	91	109	147	55	(18)
Net income (loss)	(43,078)	(41,428)	(41,199)	(59,965)	(53,306)
Earnings per share, basic USD per share	(4.16)	(2.02)	(1.99)	(2.65)	(2.04)
Earnings per share, diluted USD per share	(4.16)	(2.02)	(1.99)	(2.65)	(2.04)
Weighted average shares, basic thousands of shares	10,360	20,533	20,754	22,596	26,085
Weighted average shares, diluted thousands of shares	10,360	20,533	20,754	22,596	26,085

Fiscal years (CVRX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	142,072	106,194	90,569	105,933	75,708
Accounts receivable	2,560	5,504	7,551	9,268	10,665
Inventory	3,880	6,957	10,983	12,107	12,205
Prepaid and other current assets	2,585	4,223	2,987	2,505	3,069
Total current assets	151,097	122,878	112,090	129,813	101,647
Property and equipment, net	1,425	1,698	1,763	2,505	2,243
Right-of-use asset	0	334	1,349	1,069	878
Total assets	152,548	124,937	115,229	133,414	104,794
Accounts payable	510	1,719	1,884	2,582	3,833
Accrued liabilities	5,398	6,369	5,980	8,180	9,484
Total current liabilities	5,908	8,088	7,864	10,762	13,317
Long-term debt	0	6,747	29,222	49,273	49,514
Lease liability, non-current	0	117	1,160	877	638
Total liabilities	6,589	15,757	39,282	62,359	65,470
Accumulated deficit	(394,754)	(436,182)	(477,381)	(537,346)	(590,652)
Total stockholders' equity	145,959	109,180	75,947	71,055	39,324
Total liabilities and equity	152,548	124,937	115,229	133,414	104,794
Common shares outstanding (cover page) thousands of shares	20,478	20,690	20,928	26,036	26,312

Fiscal years (CVRX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(43,078)	(41,428)	(41,199)	(59,965)	(53,306)
Stock-based compensation	1,912	3,887	6,303	19,050	11,052
Net cash from operating activities	(27,732)	(42,677)	(39,021)	(39,144)	(40,170)
Purchases of property and equipment	1,183	685	591	1,361	580
Net cash from investing activities	(1,183)	(685)	(591)	(1,361)	(580)
Proceeds from issuing common stock	133,161	0	0	32,521	8,974
Repayments of long-term debt	21,300	0	—	—	—
Net cash from financing activities	111,883	7,493	23,984	55,870	10,520
Net change in cash	82,960	(35,878)	(15,625)	15,364	(30,225)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
CVRx	64,586	15,705	(8,826)*	26.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
LENSAR	13,565	16,495	(127)*	12.3M	106.8 quarters	Q2 FY26 10-QJun 30, 2026
TriSalus Life Sciences	46,288	11,407	(10,129)*	61.6M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
KORU Medical Systems	8,288	12,045	216*	46.2M	—	Q2 FY26 10-QJun 30, 2026
InfuSystem Holdings	964	36,933	6,777*	19.9M	—	Q2 FY26 10-QJun 30, 2026
Shoulder Innovations	24,460	17,175	(7,392)*	20.8M	13.4 quarters	Q2 FY26 10-QJun 30, 2026
Pulmonx	52,690	22,835	(3,183)*	43.6M	8.5 quarters	Q3 FY26 10-QSep 30, 2026
Venus Concept	4,312	13,776	(4,890)*	1.9M	0.9 quarters	Q3 FY25 10-QSep 30, 2025
Neuronetics	22,106	41,962	1,238*	77.7M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.